Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RSV F protein vaccine - Novavax

Drug Profile

RSV F protein vaccine - Novavax

Alternative Names: Respiratory syncytial virus fusion protein virus-like particle vaccine - Novavax; Respiratory syncytial virus vaccine - Novavax; ResVax; RSV F protein recombinant nanoparticle vaccine; RSV F Vaccine; RSV F-protein nanoparticle vaccine; RSV VLP vaccine candidate - Novavax/University of Massachusetts Medical School; RSV-F; RSV-F nanoparticle protein micelle vaccine; RSV-F VLP vaccine - Novavax; Soluble respiratory syncytial virus fusion protein vaccine

Latest Information Update: 29 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novavax
  • Class Protein vaccines; Proteins; Respiratory syncytial virus vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Respiratory syncytial virus infections

Most Recent Events

  • 12 Aug 2019 Efficacy data from the phase-III Prepare trial in Respiratory syncytial virus infections (Prevention) released by Novavax
  • 01 Jul 2019 Novavax completes a phase III trial in Respiratory Syncytial Virus Infections (Prevention) in Australia, Argentina, Chile, Spain, Mexico, India, Philippines, Bangladesh, New Zealand, South Africa, United Kingdom and USA (NCT02624947) (EudraCT2016-002302-39)
  • 10 Jun 2019 Novavax plans a phase III trial for Respiratory syncytial virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top